Navigation Links
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Date:2/11/2008

CTI to present at 2008 BIO CEO & Investor conference at the Waldorf-Astoria

in New York on Tuesday, February 12 at 1:15 PM (Eastern)

NEW YORK, Feb. 12 /PRNewswire-FirstCall/ -- BIO CEO & Investor conference -- James A. Bianco, M.D., President and CEO of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) will present an overview of the Company's sales and marketing strategy intended to grow Zevalin(R) (Ibritumomab Tiuxetan) sales above the $15 million sales figure reported for 2007. CTI completed the acquisition of Zevalin from Biogen Idec at the end of 2007.

"It is encouraging to see Zevalin U.S. sales stay steady throughout 2007 when compared to 2006 levels considering the lack of any substantial sales, marketing, or medical information effort by its prior owner on behalf of the product in 2007. We believe this steady sales figure provides a stable base from which our commercial group can grow sales for Zevalin's currently approved use in relapsed or refractory follicular non-Hodgkin's lymphoma, a market of more than 10,000 patients in the Unites States," noted Bianco.

"With new compelling clinical data, coupled with our focus on making Zevalin radioimmunotherapy readily available for medical oncologists to administer to patients in their clinics, we believe a significantly higher response rate is achievable with Zevalin over rituximab for relapsed or refractory follicular lymphoma patients following initial therapy and that such results will help grow market share from the current estimated eight percent. This is a very exciting opportunity for CTI and we expect to maximize on this product opportunity for patients and for our shareholders," Bianco continued.

Commercial Team Expansion

CTI expect
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
2. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
3. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
8. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
9. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ... Cell Therapy Market Outlook 2020 " report to ... tissue and regenerative medicine is expected to have huge ... could help in the growth of deregulated organs. Several ... are unable to form new tissue or sometimes organ ...
(Date:5/20/2015)... 20, 2015 Agricultural firm H.J. Baker ... its acquisition of Tiger-Sul. Since the purchase of ... Canada) in May 2005, H.J. Baker has leveraged the ... into a comprehensive portfolio of product offerings and solutions ... Baker and the innovation of Tiger-Sul, transforming the company ...
(Date:5/20/2015)... , May 20, 2015  Resolution Bioscience announced today ... ctDx ALK TM , a blood-based liquid biopsy for ... lung carcinoma (NSCLC), the most common form of this ... to guide patients to personalized therapies and direct them ... The Department of Health, the CLIA authority in ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... CALL DATE: Wednesday, Aug. 6, 2008 TIME: ... Dr. Candace Kendle, Chairman and CEO, ... call and,simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern ... 30, 2008. A,question and answer session will follow., Webcast Instructions, ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... Daiichi Sankyo), has received marketing,approval from the Japanese ... label extension of Biopten(R) (sapropterin dihydrochloride), which,contains the ... for the,treatment of patients with phenylketonuria (PKU). BioMarin ...
... Consent Judgment Terminating Litigation --, MADISON, N.J., ... and,Impax Laboratories Inc. today announced that all conditions ... pertaining to Impax,s proposed,generic capsule formulation of Wyeth,s ... States District Court for the District of,Delaware. The ...
Cached Biology Technology:Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 3Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 4Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 2Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 3
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... by a combination of genetic and environmental factors. For ... external influences. According to scientists from the Max Planck ... not harmful bacteria that trigger multiple sclerosis, but ... every human being needs for digestion. The researchers ...
... -- On Friday, Oct. 28 2011 the research icebreaker ... 200 scientists and technicians from research institutions in 14 ... They will examine a wide variety of topics: oceanography ... bacteria, tiny algae and animals all the way to ...
... DIEGO (Oct.27, 2011) The La Jolla ... fifth organization in the prestigious Sanford Consortium for ... for Biological Studies, The Scripps Research Institute, University ... Research Institute in the first-of-its-kind multi-institutional stem cell ...
Cached Biology News:Natural intestinal flora involved in the emergence of multiple sclerosis 2Natural intestinal flora involved in the emergence of multiple sclerosis 3RV Polarstern launches 28th Antarctic season 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 3
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... of RNase A-type ribonucleases Product Description: ,QIAGEN ... origin that binds noncovalently and inactivates a ... and C). It does not interfere with ... CL3. QIAGEN RNase Inhibitor inhibits greater than ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: